

Philip Owens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3090922/publications.pdf>

Version: 2024-02-01

43
papers

2,287
citations

257450
24
h-index

302126
39
g-index

43
all docs

43
docs citations

43
times ranked

4738
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant endocrine therapy expands stromal populations that predict poor prognosis in estrogen receptorâ€positive breast cancer. <i>Molecular Carcinogenesis</i> , 2022, 61, 359-371.	2.7	2
2	Cover Image, Volume 61, Issue 3. <i>Molecular Carcinogenesis</i> , 2022, 61, .	2.7	0
3	miR-31 Displays Subtype Specificity in Lung Cancer. <i>Cancer Research</i> , 2021, 81, 1942-1953.	0.9	11
4	Adenosine/TGFÎ² axis in regulation of mammary fibroblast functions. <i>PLoS ONE</i> , 2021, 16, e0252424.	2.5	9
5	Abstract 114: Loss of BMPR1a in fibroblasts restricts breast cancer progression and alters the immune tumor microenvironment. , 2021, , .		1
6	Mechanobiology of Bone Metastatic Cancer. <i>Current Osteoporosis Reports</i> , 2021, 19, 580-591.	3.6	6
7	Targeting the BMP Pathway in Prostate Cancer Induced Bone Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 769316.	3.5	7
8	Integrating the immune microenvironment of prostate cancerâ€induced bone disease. <i>Molecular Carcinogenesis</i> , 2020, 59, 822-829.	2.7	9
9	Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth. <i>Frontiers in Oncology</i> , 2020, 10, 357.	2.8	11
10	Myeloid Cellâ€Derived TGFÎ² Signaling Regulates ECM Deposition in Mammary Carcinoma via Adenosine-Dependent Mechanisms. <i>Cancer Research</i> , 2020, 80, 2628-2638.	0.9	28
11	Distinct tumor microenvironments of lytic and blastic bone metastases in prostate cancer patients. , 2019, 7, 293.		45
12	Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. <i>Clinical Cancer Research</i> , 2019, 25, 3352-3365.	7.0	18
13	Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER + breast cancer. <i>FASEB Journal</i> , 2019, 33, 1644-1657.	0.5	13
14	Therapeutically targeting tumor microenvironmentâ€mediated drug resistance in estrogen receptorâ€positive breast cancer. <i>Journal of Experimental Medicine</i> , 2018, 215, 895-910.	8.5	63
15	TGF-Î², Bone Morphogenetic Protein, and Activin Signaling and the Tumor Microenvironment. <i>Cold Spring Harbor Perspectives in Biology</i> , 2017, 9, a022285.	5.5	47
16	The Yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. <i>BMC Cancer</i> , 2017, 17, 88.	2.6	29
17	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. <i>Clinical Cancer Research</i> , 2017, 23, 4323-4334.	7.0	64
18	Development of Aggressive Pancreatic Ductal Adenocarcinomas Depends on Granulocyte Colony Stimulating Factor Secretion in Carcinoma Cells. <i>Cancer Immunology Research</i> , 2017, 5, 718-729.	3.4	41

#	ARTICLE	IF	CITATIONS
19	ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. <i>Breast Cancer Research</i> , 2017, 19, 105.	5.0	23
20	TÎ²RIII Expression in Human Breast Cancer Stroma and the Role of Soluble TÎ²RIII in Breast Cancer Associated Fibroblasts. <i>Cancers</i> , 2016, 8, 100.	3.7	9
21	Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition. <i>Biochemical Society Transactions</i> , 2016, 44, 1117-1134.	3.4	40
22	The Bone Microenvironment: a Fertile Soil for Tumor Growth. <i>Current Osteoporosis Reports</i> , 2016, 14, 151-158.	3.6	52
23	Bone morphogenetic protein signaling promotes tumorigenesis in a murine model of high-grade glioma. <i>Neuro-Oncology</i> , 2016, 18, 928-938.	1.2	27
24	Deletion of the BMP receptor BMPRIa impairs mammary tumor formation and metastasis. <i>Oncotarget</i> , 2015, 6, 22890-22904.	1.8	37
25	Genomic Analysis of the BMP Family in Glioblastomas. <i>Translational Oncogenomics</i> , 2015, 7, 1-9.	1.7	12
26	BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation. <i>Molecular Oncology</i> , 2015, 9, 179-191.	4.6	30
27	Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. <i>Cancer Letters</i> , 2015, 368, 79-87.	7.2	32
28	TGFÎ² Signaling in Myeloid Cells Regulates Mammary Carcinoma Cell Invasion through Fibroblast Interactions. <i>PLoS ONE</i> , 2015, 10, e0117908.	2.5	17
29	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245.	9.4	413
30	Attenuated transforming growth factor beta signaling promotes metastasis in a model of HER2 mammary carcinogenesis. <i>Breast Cancer Research</i> , 2014, 16, 425.	5.0	20
31	Role of TGF-Î² Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors. <i>Journal of Immunology</i> , 2014, 193, 3155-3164.	0.8	101
32	Stromally Derived Lysyl Oxidase Promotes Metastasis of Transforming Growth Factor-Î²-Deficient Mouse Mammary Carcinomas. <i>Cancer Research</i> , 2013, 73, 5336-5346.	0.9	164
33	Bone Morphogenetic Proteins Stimulate Mammary Fibroblasts to Promote Mammary Carcinoma Cell Invasion. <i>PLoS ONE</i> , 2013, 8, e67533.	2.5	42
34	Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2814-2819.	7.1	81
35	Deletion of TGF-Î² signaling in myeloid cells enhances their anti-tumorigenic properties. <i>Journal of Leukocyte Biology</i> , 2012, 92, 641-651.	3.3	63
36	TGF-Î² Receptor II Loss Promotes Mammary Carcinoma Progression by Th17-Dependent Mechanisms. <i>Cancer Discovery</i> , 2011, 1, 430-441.	9.4	116

#	ARTICLE	IF	CITATIONS
37	Epidermal Smad4 Deletion Results in Aberrant Wound Healing. American Journal of Pathology, 2010, 176, 122-133.	3.8	44
38	The Role of Smads in Skin Development. Journal of Investigative Dermatology, 2008, 128, 783-790.	0.7	56
39	Smad4-dependent desmoglein-4 expression contributes to hair follicle integrity. Developmental Biology, 2008, 322, 156-166.	2.0	33
40	IKK α is a critical coregulator of a Smad4-independent TGF β 2-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2487-2492.	7.1	138
41	Smad7-Induced β -Catenin Degradation Alters Epidermal Appendage Development. Developmental Cell, 2006, 11, 301-312.	7.0	144
42	Role of TGF β 2-Mediated Inflammation in Cutaneous Wound Healing. Journal of Investigative Dermatology Symposium Proceedings, 2006, 11, 112-117.	0.8	189
43	Constitutive TGF β 1 Overexpression in Mouse Keratinocytes Delays Cutaneous Wound Healing. Wound Repair and Regeneration, 2005, 13, A4-A27.	3.0	0